Investigational Drug Information for N91115
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug N91115?
N91115 is an investigational drug.
There have been 8 clinical trials for N91115.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2015.
The most common disease conditions in clinical trials are Cystic Fibrosis, Fibrosis, and Asthma. The leading clinical trial sponsors are Nivalis Therapeutics, Inc., Davita Clinical Research, and Medidata Solutions.
There are twenty-four US patents protecting this investigational drug and two hundred and seventy-two international patents.
Summary for N91115
| US Patents | 24 |
| International Patents | 272 |
| US Patent Applications | 64 |
| WIPO Patent Applications | 37 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 2 (2015-11-01) |
| Vendors | 11 |
Recent Clinical Trials for N91115
| Title | Sponsor | Phase |
|---|---|---|
| PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study | University of North Carolina, Chapel Hill | Phase 2 |
| MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9) | Nivalis Therapeutics, Inc. | Phase 1 |
Clinical Trial Summary for N91115
Top disease conditions for N91115
Top clinical trial sponsors for N91115
US Patents for N91115
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| N91115 | See Plans and Pricing | Modulators of cystic fibrosis transmembrane conductance regulator protein | AbbVie S.a.r.l. (Luxembourg, LU) Galapagos NV (Mechelen, BE) | See Plans and Pricing |
| N91115 | See Plans and Pricing | Heteroaryl substituted pyridines and methods of use | AbbVie S.a.r.l. (Luxembourg, LU) Galapagos NV (Mechelen, BE) | See Plans and Pricing |
| N91115 | See Plans and Pricing | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | AbbVie S.a.r.l. (Luxembourg, LU) Galapagos NV (Mechelen, BE) | See Plans and Pricing |
| N91115 | See Plans and Pricing | Substituted pyrrolidines and methods of use | AbbVie S.a.r.l. (Luxembourg, LU) Galapagos NV (Mechelen, BE) | See Plans and Pricing |
| N91115 | See Plans and Pricing | Solid forms of an S-Nitrosoglutathione reductase inhibitor | LAUREL THERAPEUTICS LTD. (Hangzhou, Zhejiang Province, CN) | See Plans and Pricing |
| N91115 | See Plans and Pricing | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | AbbVie S.a.r.l. (Luxembourg, LU) Galapagos NV (Mechelen, BE) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for N91115
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| N91115 | Australia | AU2017256172 | 2036-04-26 | See Plans and Pricing |
| N91115 | Brazil | BR112018072047 | 2036-04-26 | See Plans and Pricing |
| N91115 | Canada | CA3016303 | 2036-04-26 | See Plans and Pricing |
| N91115 | China | CN109219602 | 2036-04-26 | See Plans and Pricing |
| N91115 | European Patent Office | EP3448842 | 2036-04-26 | See Plans and Pricing |
| N91115 | Japan | JP2019514840 | 2036-04-26 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
